Michelle Min, MD, MS, who presented at the Fall Clinical Dermatology Conference, met with the MPR team to discuss multidisciplinary collaboration in the treatment of cutaneous lupus. empr.com/reports/video-curre…
A new liquid formulation of cevimeline HCl offers a bioequivalent alternative for adult patients experiencing dry mouth tied to Sjögren disease. empr.com/news/evoxac-oral-so…
The FDA has approved Hibsago as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure. empr.com/news/fda-approves-h…
The FDA has approved the first generic equivalent of Climara Pro, offering a once-weekly transdermal option for managing moderate to severe vasomotor symptoms. empr.com/news/fda-approves-f…
Jemperli granted accelerated approval for stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient. empr.com/news/fda-approves-d…
A potential vaccine that could prevent Alzheimer disease has been Fast Tracked by the FDA. A phase 1 trial showed promising, inducing antibodies to target the correct protofibrils and fibrils. empr.com/news/fda-fast-track…
Ryzumvi approval expanded to incorporate presbyopia. empr.com/news/ryzumvi-fda-ap…
📣 MPR Pod out now!
🔹 Once-monthly sub. long-acting formulation of olanzapine for schizophrenia;
👁️ Hovilpri for mucocutaneous HSV;
🔸 Tecentriq expanded;
🔹 Enspryng for thyroid eye disease; and
😰 Vanda’s Tx for Social Anxiety Disorder misses endpoint.
empr.com/news/mpr-weekly-dos…
Vanda Pharmaceuticals has paused the clinical program for VQW-765 after a phase 3 trial evaluating the drug for social anxiety disorder failed to show significant distress reduction compared with placebo. empr.com/news/phase-3-trial-…
Tecentriq and Tecentriq Hybreza approved in combination with a fluoropyrimidine and oxaliplatin, for the adjuvant treatment of stage III mismatch repair-deficient colon cancer. empr.com/news/fda-approves-a…
Weltruza approved as the first once-monthly long-acting injectable treatment for schizophrenia; a controlled steady release of olanzapine with no loading doses, no oral supplementation and no post-injection monitoring required. empr.com/news/once-monthly-w…
In adults and adolescents with unsuppressed HIV-1 on daily oral ART, switching to long-acting cabotegravir plus rilpivirine provided superior virologic suppression at 6 months. #HIV #Cabenuva empr.com/news/long-acting-ca…
Autus Size-Adjustable Valve approved for pediatric patients with congenital heart disease requiring surgical plumonary valve replacement. #DeviceApproval empr.com/news/fda-approves-a…
📢 New MPR Pod!
✅ New FDA approvals for Juvmo in Parkinson disease and Camzyos in pediatric obstructive hypertrophic cardiomyopathy;
🔹 Priority Review green lit for fenebrutinib in MS, and;
🫁 Sudden BLA withdrawal for a key lung cancer candidate.
empr.com/podcasts/mpr-weekly…
FDA approval of Emcitate (tiratricol) offers the first targeted therapy for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 deficiency. empr.com/news/fda-approves-e…
Graziers raw milk is being pulled from the market; more than half of those sickened are younger than five years old. empr.com/news/raw-milk-chees…
Severe alopecia treatment expanded to include coverage of patients aged 12 and older. empr.com/news/fda-approves-b…
The first selective D1/D5 dopamine receptor partial agonist, Juvmo, has been approved for Parkinson disease. #DrugApprovals empr.com/news/juvmo-tavapado…
📣 New Pod!
📋Results for weight loss Tx combo;
🔸Positive results for treatment of rare form of ALS and sefaxersen in primary IgA nephropathy;
🧬Gene Tx approved for Sanfilippo syndrome; &
🔹Lyrfigtu gains approval for FGFR2+ advanced cholangiocarcinoma. empr.com/news/mpr-weekly-dos…
Onswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApprovals empr.com/news/fda-approves-o…
